Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Libyan J Med ; 8(1): 20567, 2013 03 27.
Article in English | MEDLINE | ID: mdl-23537612

ABSTRACT

Resistance to antimicrobial agents is a major health problem that affects the whole world. Providing information on the past state of antimicrobial resistance in Libya may assist the health authorities in addressing the problem more effectively in the future. Information was obtained mainly from Highwire Press (including PubMed) search for the period 1970-2011 using the terms 'antibiotic resistance in Libya', 'antimicrobial resistance in Libya', 'tuberculosis in Libya', and 'primary and acquired resistance in Libya' in title and abstract. From 1970 to 2011 little data was available on antimicrobial resistance in Libya due to lack of surveillance and few published studies. Available data shows high resistance rates for Salmonella species in the late 1970s and has remained high to the present day. High prevalence rates (54-68%) of methicillin-resistant Staphylococcus aureus (MRSA) were reported in the last decade among S. aureus from patients with burns and surgical wound infections. No reports were found of vancomycin-resistant S. aureus (VRSA) or vancomycin-intermediate-resistant S. aureus (VISA) using standard methods from Libya up to the end of 2011. Reported rates of primary (i.e. new cases) and acquired (i.e. retreatment cases) multidrug-resistant tuberculosis (MDR-TB) from the eastern region of Libya in 1971 were 16.6 and 33.3% and in 1976 were 8.6 and 14.7%, in western regions in 1984-1986 were 11 and 21.5% and in the whole country in 2011 were estimated at 3.4 and 29%, respectively. The problem of antibiotic resistance is very serious in Libya. The health authorities in particular and society in general should address this problem urgently. Establishing monitoring systems based on the routine testing of antimicrobial sensitivity and education of healthcare workers, pharmacists, and the community on the health risks associated with the problem and benefits of prudent use of antimicrobials are some steps that can be taken to tackle the problem in the future.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial/physiology , Enterobacteriaceae Infections/epidemiology , Staphylococcal Infections/epidemiology , Tuberculosis, Multidrug-Resistant/epidemiology , Dysentery, Bacillary/epidemiology , Escherichia coli/isolation & purification , Escherichia coli Infections/epidemiology , Humans , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/isolation & purification , Libya/epidemiology , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Prevalence , Salmonella/isolation & purification , Salmonella Infections/epidemiology , Shigella/isolation & purification , Vancomycin Resistance/physiology
2.
Am J Trop Med Hyg ; 84(6): 886-91, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21633024

ABSTRACT

Stool samples from children < 5 years of age with diarrhea (N = 239) were examined for enteric pathogens using a combination of culture, enzyme-immunoassay, and polymerase chain reaction methods. Pathogens were detected in 122 (51%) stool samples; single pathogens were detected in 37.2% and co-pathogens in 13.8% of samples. Norovirus, rotavirus, and diarrheagenic Escherichia coli (DEC) were the most frequently detected pathogens (15.5%, 13.4%, and 11.2%, respectively); Salmonella, adenovirus, and Aeromonas were detected less frequently (7.9%, 7.1%, and 4.2%). The most commonly detected DEC was enteroaggregative E. coli (5.4%). Resistance to ≥ 3 antimicrobials was observed in 60% (18/30) of the bacterial pathogens. Salmonella resistance to ciprofloxacin (63.1%) has become a concern. Enteric viral pathogens were the most significant causative agents of childhood diarrhea in Tripoli. Bacterial pathogens were also important contributors to pediatric diarrhea. The emergence of ciprofloxacin-resistant Salmonella represents a serious health problem that must be addressed by Libyan health authorities.


Subject(s)
Anti-Infective Agents/therapeutic use , Ciprofloxacin/therapeutic use , Diarrhea/epidemiology , Diarrhea/microbiology , Aeromonas/drug effects , Aeromonas/isolation & purification , Aeromonas/pathogenicity , Child, Preschool , Drug Resistance, Bacterial , Escherichia coli/isolation & purification , Escherichia coli/pathogenicity , Feces/microbiology , Female , Humans , Infant , Infant, Newborn , Libya/epidemiology , Male , Norovirus/isolation & purification , Norovirus/pathogenicity , Prevalence , Rotavirus/isolation & purification , Rotavirus/pathogenicity , Salmonella/drug effects , Salmonella/isolation & purification , Salmonella/pathogenicity
3.
J Infect Dev Ctries ; 3(10): 753-61, 2009 Dec 15.
Article in English | MEDLINE | ID: mdl-20009276

ABSTRACT

Typhoid fever is endemic in the Mediterranean North African countries (Morocco, Algeria, Tunisia, Libya, and Egypt) with an estimated incidence of 10-100 cases per 100,000 persons. Outbreaks caused by Salmonella enterica serovar Typhi are common and mainly due to the consumption of untreated or sewage-contaminated water. Salmonella enterica Paratyphi B is more commonly involved in nosocomial cases of enteric fever in North Africa than expected and leads to high mortality rates among infants with congenital anomalies. Prevalence among travellers returning from this region is low, with an estimate of less than one per 100,000. Although multidrug resistant strains of Salmonella Typhi and Paratyphi are prevalent in this region, the re-emergence of chloramphenicol- and ampicillin-susceptible strains has been observed. In order to better understand the epidemiology of enteric fever in the Mediterranean North African region, population-based studies are needed. These will assist the health authorities in the region in preventing and controlling this important disease.


Subject(s)
Typhoid Fever/epidemiology , Africa, Northern/epidemiology , Anti-Bacterial Agents/therapeutic use , Congenital Abnormalities , Cross Infection/epidemiology , Cross Infection/etiology , Cross Infection/therapy , Drug Resistance, Multiple, Bacterial , Humans , Salmonella enterica/physiology , Travel , Typhoid Fever/etiology , Typhoid Fever/therapy , Typhoid-Paratyphoid Vaccines/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL